EHMT2-IN-1 - 10mM in DMSO , CAS No.2230849-55-3

CAS: 2230849-55-3 Cat. No.: E654678 Formule: C₁₈H₂₃N₇O Poids moléculaire: 353.42 PubChem CID: 135154879

GRADE & PURITY 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Vue d’ensemble

EHMT2-IN-1 is a potent EHMT inhibitor, with IC 50 s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disorder or cancer

In Vitro

EHMT2-IN-1 (Compound 108) potent EHMT inhibitor, with IC 50 s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:EHMTI PEP <100 nM (IC 50 ) EHMT2 PEP <100 nM (IC 50 ) EHMT2 ICW <100 nM (IC 50 )

Specifications

Spécifications et pureté

10mM in DMSO

Mécanismes biochimiques et physiologiques

EHMT2-IN-1 is a potent EHMT inhibitor, with IC 50 s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disorder or cancer.

Conditions de stockage de stockage

Store at -80°C

Expédié en

Dry ice packs + Cold packs

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Type d'action

INHIBITOR

Noms et identifiants

• PubChem CID: 135154879
• Poids moléculaire: 353.42

Application Protocols

No tested applications, recommended dilutions, or protocols are provided for this catalog item.

General guidance (not item-specific):

• For biochemical assays, prepare compound stocks in DMSO, confirm solubility and stability, and titrate over a relevant concentration range with appropriate vehicle controls.
• For cell-based work, assess cytotoxicity and nonspecific effects of the vehicle, verify compound recovery from plastics, and consider orthogonal target-engagement methods to corroborate results.

Please refer to your lab’s standard operating procedures and the literature pertinent to your experimental system. Validate any protocol parameters empirically.

Biological Roles

Item-specific biological activity or mechanism of action is not provided in the Product Data and should not be inferred.

General background (literature/general):

• EHMT2 (G9a) is a lysine methyltransferase that catalyzes mono- and di-methylation of histone H3 at H3K9, a mark typically associated with transcriptional repression and heterochromatin formation.
• EHMT2 often functions with EHMT1 (GLP) and can methylate non-histone substrates. It interfaces with chromatin readers of methyl-lysine and with DNA methylation machinery, contributing to epigenetic regulation.
• Chemical probes against EHMT2 are employed to interrogate epigenetic networks, study gene-expression programs, and evaluate target engagement in cells using assays such as CETSA, NanoBRET target engagement, or ChIP-based readouts of H3K9 methylation states (general methods, not item-specific performance claims).

Important: The presence of “EHMT2-IN-1” in the name does not constitute a verified activity claim for this catalog item. Consult primary literature corresponding to the exact CAS 2230849-55-3 / CID 135154879 and the item’s CoA for confirmed biological characteristics and potencies.

Buffer Applications

This product is a small-molecule screening compound and is not a buffering agent. As such, there are no specific buffer capacity or preparation guidelines applicable to the compound itself.

Practical notes (general):

• For biochemical assays, prepare dosing solutions in assay buffer (e.g., HEPES, Tris, or phosphate systems) with a constant, low percentage of DMSO as vehicle. Select buffer pH/ionic strength appropriate for the biological system under study.
• Filter and degas buffers as required by detection modality, and include vehicle-only controls to account for any buffer–vehicle interactions.

Green Alternatives

As a defined screening compound rather than a process solvent or bulk reagent, “green alternative” considerations focus on handling and solvent systems used during its application rather than replacing the active itself.

Greener handling strategies (general):

• Prefer aqueous-buffered assays with minimal DMSO (≤0.1–0.5% v/v) where compatible to reduce organic solvent usage.
• If preparative handling is required, choose safer polar solvents in place of high-toxicity options. For example, MeCN over dichloromethane for intermediate dilutions; water/MeCN gradients for LC purification.
• Use microscale experimentation and high-throughput formats to minimize material and solvent waste.
• Implement closed-container aliquoting and cold-chain logistics to reduce degradation and the need for re-synthesis.

Illustrative solvent comparison for stock preparation (general):

• DMSO: Excellent solubilizer, broadly assay-compatible at low %; not volatile, facilitates accurate dosing; higher E-factor when used in volume.
• MeCN: Good for LC/analytical work; more volatile, easier to remove; less effective for some heteroaromatic inhibitors.
• Ethanol/MeOH: Useful co-solvents; may affect certain assay readouts; flammable.

No greener substitute for the active compound itself is proposed here, as its identity is integral to the intended research use.

Pharmaceutical Uses

No pharmacopeial grade, excipient role, or formulation status is provided for this item. It is supplied for research use only and is not intended for human or veterinary use.

General considerations for small-molecule tools (not item-specific):

• In preclinical research settings, compounds of this type may be formulated for in vitro or exploratory in vivo studies using co-solvent or lipid-based systems; however, such uses require comprehensive characterization (purity, stability, polymorph/salt form) and are outside the scope of this catalog entry.
• No USP/EP/JP monograph applicability is indicated. Do not use in GMP manufacturing or clinical formulations without appropriate qualification and regulatory assessment.

Physical Properties

Item-specific properties (specifications):

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.
• LogP, pKa, refractive index: Not specified for this item; refer to CoA/Spec Sheet.

General expectations for small-molecule screening compounds (literature/general):

• Many EHMT-family tool compounds are aromatic, heteroatom-rich molecules supplied as solids and handled as DMSO stocks for in vitro assays. Typical working stock concentrations range from 1–10 mM in anhydrous DMSO (general practice; not item-specific guidance).
• If the compound is neutral to weakly basic, it may show limited aqueous solubility and better solubility in polar aprotic solvents (e.g., DMSO, DMF) compared with water or alcohols; confirm with item-specific data before use.

Important: Do not substitute general expectations for specifications. Use the item’s CoA/Spec Sheet for authoritative physical property values.

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

Guidance on interpreting quality for screening compounds (general):

• For discovery biology and chemical probe work, researchers commonly require ≥95% purity by HPLC/UPLC and identity confirmation by MS/1H NMR. Since the specific purity grade is not provided here, confirm the exact specification on the CoA.
• If a stabilizer, salt form, or solvate/hydrate is used, these details impact molecular weight, stock solution preparation, and assay dosing. This item’s stabilizer/salt status is not specified; confirm on the Spec Sheet.
• Low non-volatile residue and low UV background are useful for plate-based detection methods (fluorescent/absorbance assays). If such attributes are critical, request the analytical package or batch-specific CoA.
• Trace impurities can influence cellular readouts and enzymology; include proper vehicle controls and, when possible, confirm activity with an orthogonal assay or a second lot.

Documentation:

• For audit trails, retain a copy of the CoA, batch number, and any analytical spectra supplied with the shipment. These constitute the authoritative quality record for the specific lot you receive.

Reaction and Applications

This product is marketed as a discrete small-molecule compound for research screening and chemical biology. It is not typically used as a synthetic reagent or catalyst.

Research use scenarios (general, not item-specific claims):

• Preparation of DMSO stock solutions for biochemical or biophysical assays investigating chromatin-modifying enzyme pathways.
• Use in in vitro enzymology, thermal shift assays (DSF), fluorescence polarization, or TR-FRET binding formats to explore structure–activity relationships in discovery programs.
• Application in cell-based assays may require vehicle controls, solubility/precipitation checks, and assessment of cytotoxicity windows.

Practical tips (general):

• Verify identity/purity by LC–MS and HPLC prior to critical studies.
• If light-sensitive or hygroscopic (unknown for this item), minimize exposure; aliquot and store at the recommended temperature (−80°C) to reduce freeze–thaw cycles.
• Use matched controls and, where possible, a chemotype-distinct comparator to validate phenotype specificity.

Note: No manufacturer application notes were provided for this catalog entry. Do not infer specific biological activity or potency for this item without consulting the CoA/SDS or primary literature linked to the exact CAS/CID and lot.

Reaction Conditions

Not typically applicable. This product is not used as a reagent or catalyst in chemical synthesis, so there are no recommended “reaction conditions” specific to it.

General handling conditions for assay preparation (literature/general):

• Prepare concentrated DMSO stock solutions (e.g., 1–10 mM) if solubility permits; vortex and, if necessary, briefly sonicate to aid dissolution. Filter sterilization is often avoided to reduce compound loss.
• Upon dilution into aqueous assay buffers, maintain a constant vehicle percentage across controls and treated samples. Mix thoroughly to prevent precipitation; inspect visually for clarity.
• Temperature: most biochemical assays are conducted at room temperature to 37°C; exact conditions depend on the enzyme/cell system and detection method.
• Stability: limit freeze–thaw cycles by preparing single-use aliquots; protect from moisture and light as a precaution unless the CoA indicates exceptional stability.

Note: These are general practices for small-molecule screening compounds and do not constitute item-specific specifications.

Safety and Handling

Item-specific hazard information:

• GHS Classification: Not specified for this item; refer to SDS.
• Signal Word: Not specified for this item; refer to SDS.
• H-Statements/Pictograms: Not specified for this item; refer to SDS.

General laboratory safety guidance (not item-specific; follow SDS as primary source):

• Handle in a chemical fume hood with appropriate PPE: lab coat, safety glasses, and suitable chemical-resistant gloves.
• Avoid inhalation of dust/aerosols and prevent skin/eye contact. Wash thoroughly after handling.
• For unknown toxicity small molecules, minimize exposure and practice prudent micro-scale handling.
• Storage incompatibilities (general): segregate from strong oxidizers and strong acids/bases unless compatibility is confirmed by the SDS.
• First aid (general): in case of skin/eye contact, rinse with water for at least 15 minutes; if inhaled, move to fresh air; if ingested, rinse mouth. Seek medical attention as needed. Provide SDS to responders.
• Spill response: absorb small spills with inert material, avoid dust generation, and dispose in accordance with local regulations.

Shipping/Storage (from Product Data):

• Shipped in dry ice packs + cold packs.
• Storage: Store at -80°C. Keep container tightly closed, protected from light and moisture. Allow to equilibrate to room temperature in a desiccated environment before opening to minimize condensation.

Solvent Selection

Item-specific solubility/miscibility is not provided in the Product Data. Use the CoA/Spec Sheet and exploratory solubility tests to confirm.

General solvent guidance for small-molecule screening compounds (literature/general):

• Primary stock solvent: Anhydrous DMSO is typically preferred due to broad solubilizing power and compatibility with biochemical assays at ≤0.1–1% v/v in final wells.
• Alternative polar aprotics: DMF or NMP can be used when DMSO solubility is insufficient; assess assay tolerance carefully.
• Aqueous systems: If limited aqueous solubility is observed, prepare concentrated DMSO stocks and dilute into buffered media with vigorous mixing. Consider co-solvent strategies (≤10–20% PEG-400, or small % of ethanol) only if assay-compatible.
• Volatile organics (MeCN, MeOH, EtOH): can aid intermediate dilutions but may be less effective than DMSO for heteroaromatic inhibitors.

Polarity and compatibility (general):

• Many enzyme inhibitors are moderately lipophilic; adsorption to plastics can occur at low nM–µM levels. Use low-bind tubes/plates and verify recovery.
• Filter sterilization can cause analyte loss; avoid unnecessary filtration and pre-wet membranes if required.

Always validate solvent choice empirically for your assay system and maintain constant vehicle concentration across control and treated samples.

Storage and Reconstitution

From Product Data (item-specific):

• Storage Conditions: Store at −80°C.
• Shipped In: Dry ice packs + cold packs.

General best practices (supplemental, not item-specific specs):

• Upon receipt, keep the container cold and allow to equilibrate in a desiccator to ambient temperature before opening to avoid condensation.
• If supplied as a solid, aliquot into small single-use vials under dry, inert atmosphere if possible. If supplied as a solution, keep tightly closed and minimize headspace.
• For working solutions, dissolve in anhydrous DMSO (if compatible) to prepare concentrated stocks. Filter only if necessary due to potential adsorption losses. Record exact concentration by weight or quantitative NMR where precision is required.
• Avoid repeated freeze–thaw cycles; store aliquots at −80°C and keep a limited-use aliquot at −20°C or 4°C short-term if stability allows (confirm with CoA/Spec).
• Protect from light and moisture as a precaution unless stability data indicate otherwise.

Research Use Note: For research use only. Not for human or veterinary use.

Structure and Identity

• Product name: EHMT2-IN-1 (SKU: E654678)
• CAS: 2230849-55-3
• PubChem CID: 135154879
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

Notes on identity and context (general information):

• Naming indicates a small-molecule inhibitor candidate for the lysine methyltransferase EHMT2 (G9a); however, target details for this catalog item are not confirmed in the provided Product Data and should not be inferred as specifications.
• Without a disclosed structure, specific functional groups, stereochemistry, and ring systems cannot be detailed for this item. Consult the Certificate of Analysis (CoA) or Structure Sheet if available for definitive structural information.
• This product is listed under “小分子和化合物库,” suggesting use as a screening or probe-like compound for research applications in chemical biology or discovery workflows.

Synthetic Utility

This product is intended as a final small-molecule entity for screening or probing biological systems and is not typically employed as a synthetic reagent, monomer, or building block.

General commentary (literature/general):

• Many epigenetic tool compounds contain multiple heteroatoms and tailored pharmacophore features (e.g., basic amines, amide/urea motifs, heteroaromatic cores) optimized for target binding. Such structures have limited modularity as commodity building blocks.
• If derivatization is desired (e.g., for SAR or probe development), synthetic campaigns usually start from earlier intermediates rather than the final inhibitor. Late-stage functionalization (LSF) can sometimes introduce reporter handles (alkynes/azides) for chemical biology applications, but feasibility is highly structure-dependent and requires knowledge of the exact scaffold (not provided here).

Conclusion: Treat this item as a target-screening compound rather than a synthetic auxiliary. For synthetic planning, request the structure or consider procuring structurally related intermediates designed for diversification.

Target Specificity

No target specificity, binding partner, or selectivity profile is provided in the Product Data for this item. Do not infer specificity from the product name.

For confirmed target information (if required for your study), consult:

• The batch-specific CoA/Spec Sheet.
• Primary literature associated with CAS 2230849-55-3 / CID 135154879.
• Independent profiling data (e.g., enzymatic panels) generated under your assay conditions.